Literature DB >> 1146927

Comparative studies of the ethynyl estrogens used in oral contraceptives. II. Antiovulatory potency.

J W Goldzieher, A Pena, C B Chenault, T B Woutersz.   

Abstract

The occurrence or inhibition or ovulation was inferred from the plasma progestin level measured in the last week of 430 control cycles and of 4,638 cycles from fertile women receiving various antiovulatory steroids, singly and in combination. The substances tested included: mestranol and ethynylestradiol (EE) of homogeneous bioavailability, used alone in a range from 50 to 100 mug per day; these same dose levels combined with various progestins; and finally various proprietary combination and sequential low-dose regimens undergoing clincial trials. Statistical analysis showed ethynylestradiol and mestranol alone to be equipotent over the tested range, although at 50 mug per day superiority of mestranol over EE was suggested. Two preparations of EE at 50 mug per day, one of them a sequential with dimethisterone, showed different potency. At 50 mug per day no estrogen, alone or with a sequential progestin, reached a satisfactory level of effectiveness. However, very small amount in the range of 20 to 40 mug per day were highly effective when combined with quantities of various 19-nor progestins which by themselves are well below the antiovulatory level. This indicated that a synergism exists between these two classes of compounds insofar as their antiovulatory effect is concerned, thus explaining the high contraceptive effectiveness observed with very-low-dose combination regimens.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 1146927     DOI: 10.1016/0002-9378(75)90061-7

Source DB:  PubMed          Journal:  Am J Obstet Gynecol        ISSN: 0002-9378            Impact factor:   8.661


  2 in total

Review 1.  Clinical pharmacokinetics of oral contraceptive steroids.

Authors:  M L Orme; D J Back; A M Breckenridge
Journal:  Clin Pharmacokinet       Date:  1983 Mar-Apr       Impact factor: 6.447

2.  Contraceptive efficacy of oral and transdermal hormones when co-administered with protease inhibitors in HIV-1-infected women: pharmacokinetic results of ACTG trial A5188.

Authors:  Mary A Vogler; Kristine Patterson; Lori Kamemoto; Jeong-Gun Park; Heather Watts; Francesca Aweeka; Karin L Klingman; Susan E Cohn
Journal:  J Acquir Immune Defic Syndr       Date:  2010-12       Impact factor: 3.731

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.